Sleep Disorders in the Geriatric Population: Implications for Health
CME Information Sleep Disorders in the Geriatric Population:
Implications for Health This activity is made possible by an educational grant from Takeda Pharmaceuticals North America, Inc.
Target Audience This activity is based upon a symposium offered at the 2005 American Geriatrics Society Annual Meeting in Orlando, Florida. It is intended for internal medicine physicians, family practitioners, geriatricians, general practitioners, cardiologists, neurologists, psychiatrists, geriatric psychiatrists, and physician’s assistants.
Educational Objectives Upon completion of this activity, participants should be able to:
• Describe the diagnosis, consequences, and treatment, both pharmacologic and nonpharmacologic, of insomnia in the older adult.
• Summarize the effects, diagnosis, and options for treatment of circadian rhythm disturbances in the older adult.
• Discuss the symptoms, impact, and treatment of various sleep disorders in the geriatric population.
• Describe the interaction between medical illness and sleep quality in the older adult.
• Explain the relationship between dementia and sleep disturbance.
Program Completion Time Based upon trials, the estimated time to complete this activity is 1 hour. Accreditation The American Geriatrics Society is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Continuing Education Hours The American Geriatrics Society designates this continuing medical education activity for up to 1 hour of Category 1 credit toward the Physician’s Recognition Award of the American Medical Association. Each physician should claim only those hours of credit that he/she actually spent in the activity.
Obtaining Continuing Medical Education Credit To receive credit, physicians must complete the CME Examination that appears at the end of this program and fax or mail to: American Geriatrics Society The Empire State Building 350 Fifth Ave, Suite 801 New York, NY 10118 Fax: (212) 832-8646 Attn: Dennise McAlpin A minimum score of 70% on the CME Examination is required for credit. A certificate of completion will be mailed within 4 weeks of receipt of the completed answer sheet.
Faculty Disclosure of Financial Interests As an accredited provider of Continuing Medical Education, the American Geriatrics Society continuously strives to ensure that the education activities planned and conducted by our faculty meet generally accepted ethical standards as codified by the ACCME, the Food and Drug Administration, and the American Medical Association’s Guide for Gifts to Physicians. To this end, we have implemented a process wherein everyone who is in a position to control the content of an education activity has disclosed to us all relevant financial relationships with any commercial interests as related to the content of their presentations, and under which we work to resolve any real or apparent conflicts of interest. Faculty conflicts of interest in this particular CME activity have been resolved by having the content independently peer reviewed before publication. Michael Malone, MD, served as the peer reviewer on behalf of the AGS Program Committee, and Cathy Alessi, MD, served as a content expert peer reviewer.
Peer Reviewer Disclosures: Drs. Malone and Alessi have no financial relationships with commercial interests. All faculty were independently selected by the organizing committee for the 2005 Annual Scientific Meeting of the American Geriatrics Society, upon which this supplement is based. Those faculty members who disclosed affiliations or financial interests with the commercial interests involved with the products or services to which they may refer are listed below. We have also noted if a faculty member indicates that she/he will be discussing a commercial product or an off-label or investigational use. Dr. Sonia Ancoli-Israel reported that she is a member of the speaker’s bureau for King Pharmaceuticals, Inc., Neurocrine Biosciences, Inc./Pfizer Inc, Sanofi-Aventis, Sepracor Inc., and Takeda Pharmaceuticals North America, Inc. She is also a consultant to and a member of the scientific advisory board of Cephalon, Inc., King Pharmaceuticals, Neurocrine/Pfizer, Neurogen Corporation, Pfizer Inc, Sanofi-Aventis, Sepracor, Somaxon Pharmaceuticals, Inc., and Takeda Pharmaceuticals. Her presentation will not discuss the unapproved use of any drug or device. Dr. Steven R. Barczi reported that he was a member of the speaker’s bureau for Sepracor Inc. His presentation will not discuss the unapproved use of any drug or device. Dr. Alfred J. Lewy reported no financial relationships with commercial entities. His presentation will not discuss the unapproved use of any drug or device. Dr. Jennifer L. Martin reported no financial relationships with commercial entities. Her presentation will discuss an unlabeled use of a commerical product or an investigational use not yet approved for any purpose. Dr. Barbara Phillips reported that she is a member of advisory boards, panels, and task forces for AstraZeneca Pharmaceuticals LP, Boehringer Ingelheim Pharmaceuticals, Inc., COPD CCRN, NHLBI Observatioinal Study Monitoring Board (OSMB) for the CARDIA Study, GlaxoSmithKline, National Institutes of Health (NIH) Data Safety and Monitoring Board, NIH Patient-Oriented Research Career Development Awards Panel, ResMed Corp., and Sanofi-Aventis. She also serves as a paid consultant for Henry Watz Gardner Sellars & Gardner, PLLC, Lexington, KY, and Ogden Newell & Welch, PLLC, Louisville, KY; and is a member of the speaker’s bureau for Boehringer Ingelheim, GlaxoSmithKline, Jewish Heart Lung Institutes, Louisville KY, Medical College of Georgia, Pfizer, ResMed, St. Joseph’s Hospital, Burbank, CA, Swedish Medical Center, Seattle, WA, and University of South Carolina College of Medicine. Her presentation will not discuss the unapproved use of any drug or device. Disclaimer The content and views presented in this educational activity are those of the faculty and do not necessarily reflect those of the American Geriatrics Society, Takeda Pharmaceuticals, or the publisher, HMP Communications, LLC. The authors have disclosed if any unlabeled use of products is mentioned in the material. Before prescribing any medicine, primary references and full prescribing information should be consulted. Program Release Date: December 2005 Program Expiration Date: December 2006